About

At DASPO, we conduct methodologically rigorous quantitative research on survival analysis and related topics within personalised oncology. Our work focuses on developing innovative statistical methods to evaluate and optimise multimodal treatment strategies in fighting cancer. We are also committed to the robust application and adaptation of established statistical methodologies in clinical cancer research.

The group was established in June 2015, with its first KiKa-funded project evaluating chemotherapy regimens and survival outcomes in patients with osteosarcoma.

Projects

DASPO is currently conducting several research projects in personalised oncology, covering a range of topics including therapy modifications such as treatment delays and dose reductions caused by acute toxicity.

The group is leading two major projects on Ewing Sarcoma:

• INDICATES  (funded by KWF), developing a clinical prediction tool for INDIvidualized loCAl Therapy;

• PACT-ES (funded by KiKa), exploring a novel Personalised Approach to Chemotherapy Treatment.

Supported by KWF, DASPO developed a dynamic prognostic model that predicts survival and local recurrence under different treatment protocols in patients extremity soft-tissue sarcoma (eSTS), based on individual and tumour characteristics. This model is implemented in the PERSARC (PERsonalised SARComa Care) app, now an integral decision-support tool for many physicians in daily-practice.
Building on the established validity of PERSARC, DASPO collaborates with several European projects using PERSARC as a mathematical framework to improve knowledge and treatment strategies in eSTS.

The group also contributes to the statistical methodologies and analysis of multiple clinical studies, including: PRIME-ROSE, DRUP, SCOPES, and PASART-II clinical trial.

Explore our research projects | Explore our GitHub page